Repeat OnabotulinumtoxinA Treatment in Spinal Cord Injury Patients with Neurogenic Detrusor Overactivity: Final Analysis of 4 Years’ Follow-up Confirms Sustained Safety and Efficacy

Kennelly M1, Schulte-Baukloh H2, Dmochowski R3, Ethans K4, Moore C5, Zheng Y6, Guard S7, Jenkins B8, Karsenty G9

Abstract Category


Abstract 375
Innovative Therapies
Scientific Podium Poster Session 24
Wednesday 22nd October 2014
17:15 - 17:20
Room 1
Detrusor Overactivity Incontinence Quality of Life (QoL) Spinal Cord Injury
1. Carolinas Rehabilitation, Charlotte, NC, USA, 2. Hedwig-Krankenhaus, Berlin, Germany, 3. Vanderbilt University, Nashville, TN, USA, 4. University of Manitoba, Winnipeg, Manitoba, CA, 5. Cleveland Clinic, Cleveland, OH, USA, 6. Allergan, Inc., Bridgewater, NJ, USA, 7. Allergan, Inc, Marlow, UK, 8. Allergan, Inc, Irvine, CA, USA, 9. Aix-Marseille Universite, Marseille, France

Michael Kennelly